STAB1 and atherosclerosis: These findings bear consequences for the use of therapeutical inhibition of Stabilins, which for Stab1 is already in Phase 2 clinical trials in cancer (Virtakoivu et al., 2021) and might be a treatment option for atherosclerosis in future studies (Manta et al., 2022).